Evotec AG to Re-Engineer Drug Discovery and Development Operations, Lays Off 45; U.S. Operations Will be Wound Down With Immediate Effect

Published: May 06, 2009

HAMBURG, Germany, May 5, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) announced today that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and development operations to improve efficiency and realize further cost saving potential.

Back to news